Cushing’s Syndrome – Opportunity Assessment and Forecast to 2030
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
GlobalData estimates that 2020 sales for Cushing’s syndrome (CS) therapies were approximately $121.4 million, with the US and Germany dominating the market. The sales are expected to grow at a CAGR of more than 10% during 2020-2030. GlobalData expects the number of diagnosed prevalent cases of Cushing’s syndrome (CS) to be 25,625 cases in 2020, increasing at a negligible Annual Growth Rate (AGR) of less than 1% across the two major markets.
In 2020, the US had the highest number of diagnosed prevalent cases of CS (endogenous), followed by Germany. There are currently two therapies in the late-stage pipeline: Recorlev (levoketoconazole), which is in pre-registration in the US, and Relacorilant which is in Phase III in the EU and US.
Cushing’s Syndrome Market Overview
For more insights on this report, download a free report sample
What are the treatment options available for Cushing’s syndrome?
In patients with overt CS, the treatment recommendation is to normalize cortisol levels or alter the response of cortisol receptors to eliminate the signs and symptoms of CS. Treatments designed to normalize cortisol or its action, are not recommended when there is only a borderline abnormality in the hypothalamic-pituitary-adrenal (HPA) axis without any specific signs of CS. Unilateral resection should be carried out in all cases of benign unilateral disease. ACTH-secreting tumors need to be localized and resected with node dissection. Transsphenoidal selective (TSS) adenectomy is the optimal treatment for CD in pediatric and adult patients.
Some of the essential molecules or drugs recommended for the treatment of CS include Korlym (mifepristone), Isturisa (osilodrostat phosphate), Signifor (pasireotide), Signifor LAR (pasireotide), Ketoconazole (ketoconazole), Metopirone (metyrapone), and Lysodren (mitotane).
What are the market dynamics of Cushing’s syndrome?
The launch of three new treatments across the forecast period – Recorlev, Relacorilant, and SPI-62 will drive an increase in the overall market size of CS as more efficacious therapeutic options to become available to patients. The increasing access of patients in the EU, specifically Germany, to the novel steroidogenesis inhibitor Isturisa will drive the growth of the CS market and erode the market share of more traditional, less effective therapies such as ketoconazole and Metyrapone.
The lack of late-stage pipeline products for CS represents an opportunity for companies to help develop transformational therapies to expand treatment options by developing trials with meaningful primary endpoints beyond plasma cortisol reduction, which is often used for therapies in development. A need remains for efficacious therapies that target the underlying cause of CD. There is steadily increasing awareness among physicians regarding CS symptomatology as novel therapies enter the market.
What are the major drugs for Cushing’s syndrome?
Signifor/Signifor LAR, Korlym, Isturisa, Metopirone, Lysodren, and Ketoconazole (branded and generic) are the major drugs in Cushing’s syndrome market.
Market report scope
Market size (Year – 2020) | $121.4 million |
Growth rate | CAGR of >10% from 2021 to 2030 |
Base year for estimation | 2020 |
Forecast period | 2021-2030 |
Key Drugs | Signifor/Signifor LAR, Korlym, Isturisa, Metopirone, Lysodren, and Ketoconazole (branded and generic). |
Key Therapies | Steroidogenesis Inhibitor, GR-II Antagonist, and SPI-62. |
Companies covered | Corcept Therapeutics Inc., Recordati SpA, Laboratorie HRA Pharma SAS, Strongbridge Biopharma PLC., and Sparrow Pharmaceuticals. |
GlobalData’s “Cushing’s Syndrome – Opportunity Assessment and Forecast to 2030” combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the CS market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the CS market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of the various competitor.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
Recordati SpA
Laboratorie HRA Pharma SAS
Strongbridge Biopharma PLC.
Sparrow Pharmaceuticals
Table of Contents
Figures
Frequently asked questions
-
What was Cushing’s syndrome market value in 2020?
The total Cushing’s syndrome market value was $121.4 million in 2020.
-
What is the growth rate of the Cushing’s syndrome market?
The sales in Cushing’s syndrome are expected to grow at a CAGR of more than 10% during 2020-2030.
-
What are the key drugs for Cushing’s syndrome?
Key drugs for Cushing’s syndrome include Signifor/Signifor LAR, Korlym, Isturisa, Metopirone, Lysodren, and Ketoconazole (branded and -generic).
-
What are the key therapies for Cushing’s syndrome?
Key therapies for Cushing’s syndrome include Steroidogenesis Inhibitor, GR-II Antagonist, and SPI-62.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.